SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile sparked a sharp selloff in T-Mobile and other wireless carriers as traders weighed the prospect of a new competitor. The community is divided between seeing a meaningful long-term threat and calling the reaction excessive because building a competitive network would take substantial time and investment.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

SpaceXs agreement to acquire low-band spectrum for Starlink Mobile has intensified concerns about future competition, weighing on AT&T and other major wireless carriers. Traders are split between viewing the sharp selloff as an overreaction given the time and infrastructure needed to build a rival network and seeing a credible long-term threat; some are buying the dip for AT&Ts dividend.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is drawing attention amid a steep, sustained share-price decline that investors say lacks a clear explanation, with frustration focused on managements limited communication. The debate centers on whether Auvelitys Alzheimers agitation launch is gaining traction: bulls cite rising prescriptions and possible data undercounting, while skeptics question whether uptake is accelerating enough to support growth and a path to profitability.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax rallied alongside vaccine peers after reports of an NIH push to accelerate personalized cancer vaccines, with traders noting the move was largely sector-wide sympathy buying rather than a company-specific oncology announcement. The community also debated whether heavy short interest could amplify the move, while some pointed to Sanofis combination-vaccine trial as a separate potential catalyst.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunruns distributed AI-computing pilot, which would use customers solar-and-battery-equipped homes to host computing nodes, is driving attention and enthusiasm about a new data-center power opportunity. Traders are debating whether the concept can generate meaningful revenue, since the rollout is early and its economics remain unclear.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the following business segments: Consumer and Business. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

SpaceXs planned acquisition of low-band spectrum for Starlink Mobile has raised fears that it could eventually compete with Verizon and other U.S. wireless carriers, weighing heavily on telecom shares. Traders are divided between viewing the move as a long-term threat and calling the selloff an overreaction given the years of investment and infrastructure needed to build a competing network; some see Verizons dividend and cash flows as support.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is rallying to fresh highs amid strength in software stocks, with traders highlighting its breakout and momentum. Bulls point to AI-related observability demand, while skeptics warn that the valuation is stretched and the move could reverse.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Nasdaq-100 reentry and a reported NIH effort to accelerate personalized cancer vaccines have fueled buying, alongside optimism about its partnered mRNA melanoma-vaccine program with Merck. Traders are divided over whether index-related demand and cancer-vaccine hopes justify the sharp run, with skeptics pointing to valuation and ongoing losses and warning of a pullback.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

A joint request to extend claim-construction briefing deadlines in Aurinias generic-voclosporin patent litigation has fueled speculation that settlements may be nearing, though none is confirmed. Traders welcomed the share-price rebound, while others expect it to fade and remain frustrated by continued delays and limited company updates.

WorldFinancial

Speculation that USD1s use at the UFC Freedom 250 event could boost attention to WLFI is drawing bullish calls for a squeeze, alongside recurring hopes that the bank-charter development will add utility. Skeptics counter that WLFI has lagged other crypto assets and question whether these developments will benefit token holders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Brief India: Aequitas: JSW Cement IPO Lockup Expiry - US$180m Lockup Release, But Shares Have Traded Down and more

In this briefing: Aequitas: JSW Cement IPO Lockup Expiry - US$180m Lockup Release, But Shares Have Traded Down Aditya Birla Capital (ABCAP IN): Global Index Inclusion & Big Impact HSIE Results Daily: BSE, Navin Fluorine International, The Ramco Cements... Healthcare Global Enterprises Ltd - Guiding Steady Growth Ahead Jyothy Labs Ltd - Volumes Drive a Steady Quarter; Maintain HOLD 1. Aequitas: JSW Cement IPO Lockup Expiry - US$180m Lockup Release, But Shares Have Traded Down JSW Cement Limited (9858514Z IN) raised around US$410m in its IPO in August 2025. The lockup on its pre-IPO investors is set to expire soon. JSW Cement (JSWC) is a cement manufacturing company in India focused on manufacturing green cementitious products comprising blended cement, ordinary portland cement, ground granulated blast furnace slag, among other products. In this note, we will talk about the lockup dynamics and possible placement. 2. Aditya Birla Capital (ABCAP IN): Global Index Inclusion & Big Impact Aditya Birla Capital Ltd (ABCAP IN) will be added to a global index later this month and passive trackers will need to buy a significant number of days of ADV.

Brief India: Aditya Birla Capital (ABCAP IN): Global Index Inclusion & Big Impact and more

In this briefing: Aditya Birla Capital (ABCAP IN): Global Index Inclusion & Big Impact HSIE Results Daily: BSE, Navin Fluorine International, The Ramco Cements... Healthcare Global Enterprises Ltd - Guiding Steady Growth Ahead Jyothy Labs Ltd - Volumes Drive a Steady Quarter; Maintain HOLD Mahanagar Gas Ltd - Largely Inline Q3; Volume Growth on Track 1. Aditya Birla Capital (ABCAP IN): Global Index Inclusion & Big Impact Aditya Birla Capital Ltd (ABCAP IN) will be added to a global index later this month and passive trackers will need to buy a significant number of days of ADV. The impact in terms of delivery volume to buy is much higher and the stock looks underpositioned relative to the estimated passive buying. Aditya Birla Capital Ltd (ABCAP IN) could outperform peers in the short-term and there will be profit taking closer to implementation of the changes. 2. HSIE Results Daily: BSE, Navin Fluorine International, The Ramco Cements... BSE: BSE delivered a strong quarter with revenue rising 16.4% QoQ and 60.8% YoY, led by sustained traction in transaction revenue and strong book-building and listing fees Adjusted PAT (ex-labor laws provision, additional SGF, and impairment) came in at INR 6.5bn vs our estimate of INR 6.2bn Transaction revenue, contributing 77% of total revenue, surged 26% QoQ on continued gains in options market share and recovery in industry volumes Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief India: HSIE Results Daily: BSE, Navin Fluorine International, The Ramco Cements... and more

In this briefing: HSIE Results Daily: BSE, Navin Fluorine International, The Ramco Cements... Healthcare Global Enterprises Ltd - Guiding Steady Growth Ahead Jyothy Labs Ltd - Volumes Drive a Steady Quarter; Maintain HOLD Mahanagar Gas Ltd - Largely Inline Q3; Volume Growth on Track Embassy Office Parks REIT Ltd - Q3FY26: Strategic Expansion and Rental Upside to Drive Growth 1. HSIE Results Daily: BSE, Navin Fluorine International, The Ramco Cements... BSE: BSE delivered a strong quarter with revenue rising 16.4% QoQ and 60.8% YoY, led by sustained traction in transaction revenue and strong book-building and listing fees Adjusted PAT (ex-labor laws provision, additional SGF, and impairment) came in at INR 6.5bn vs our estimate of INR 6.2bn Transaction revenue, contributing 77% of total revenue, surged 26% QoQ on continued gains in options market share and recovery in industry volumes Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief India: Wakefit Innovations Ltd IPO- Forensic Analysis and more

In this briefing: Wakefit Innovations Ltd IPO- Forensic Analysis India: RBI Cuts 25bp but the Real Policy Rate Is Still Too High at +5% India: Goldilocks Gives Way to Constraints Wakefit Innovations IPO: Blending Digital DNA With Offline Ambition Healthcare Global Enterprises Ltd - 5 Th December, 2025 1. Wakefit Innovations Ltd IPO- Forensic Analysis Wakefit Innovations (1684049D IN) 's INR 12.9 bn IPO is a combination of fresh issue worth INR 3.8 bn and OFS component worth INR 9.1 bn. Wakefit is among the top 3 companies in the organised mattress market and has been growing much faster than its rival B2C companies. Wakefit’s turnaround in profitability in H1FY26 however relies on other income, inventory changes and A&P spends. Moreover, stagnant provisions for loyalty, and slow moving inventory warrant attention 2. India: RBI Cuts 25bp but the Real Policy Rate Is Still Too High at +5% RBI's MPC cut 25bp as expected, but it remains behind the curve, with the real policy rate now excessively high at +5%.

Brief India: India: RBI Cuts 25bp but the Real Policy Rate Is Still Too High at +5% and more

In this briefing: India: RBI Cuts 25bp but the Real Policy Rate Is Still Too High at +5% India: Goldilocks Gives Way to Constraints Wakefit Innovations IPO: Blending Digital DNA With Offline Ambition Healthcare Global Enterprises Ltd - 5 Th December, 2025 Sedemac Mechatronics Ltd Pre-IPO Tearsheet 1. India: RBI Cuts 25bp but the Real Policy Rate Is Still Too High at +5% RBI's MPC cut 25bp as expected, but it remains behind the curve, with the real policy rate now excessively high at +5%. RBI inflation forecasts were and remain too high. Food deflation is likely to be shortlived, with vegetable prices rising MoM since May'25. But all other food and non-food inflation components are moderating, and GST cuts impart further disinflation. We expect inflation to be 1.8%YoY in Q4FY26 (vs RBI's 2.9%YoY forecast), 2.3% and 2.5% in Q1 and Q2FY27, so expect another 75bp reduction in repo rate by Aug'26. 2. India: Goldilocks Gives Way to Constraints RBI cuts repo rate by 25bps to 5.25% as expected, citing exceptional disinflation (0.25% October CPI) and 8.2% growth, though maintaining a neutral stance signals easing cycle may be nearing end.

Brief India: India: Goldilocks Gives Way to Constraints and more

In this briefing: India: Goldilocks Gives Way to Constraints Wakefit Innovations IPO: Blending Digital DNA With Offline Ambition Healthcare Global Enterprises Ltd - 5 Th December, 2025 Sedemac Mechatronics Ltd Pre-IPO Tearsheet Exencial Industry Tidings 05/12/2025 1. India: Goldilocks Gives Way to Constraints RBI cuts repo rate by 25bps to 5.25% as expected, citing exceptional disinflation (0.25% October CPI) and 8.2% growth, though maintaining a neutral stance signals easing cycle may be nearing end. It forecasts headline inflation to fall to 0.6% in Q3 before rebounding sharply to 2.9% and 3.9% subsequently, limiting the scope for additional rate cuts despite growth moderating from current highs. Durable liquidity injections alongside rate cuts acknowledge monetary transmission constraints. The consensus sees 5.25% as the terminal rate, with policy dependent on inflation normalisation and external sector stability. This content is sourced through publicly available sources and has been machine generated.

Brief Equities Bottom-Up: Halyk Bank — 7% NIM likely to be sustained into 2026 and more

In this briefing: Halyk Bank — 7% NIM likely to be sustained into 2026 Wakefit Innovations IPO: Blending Digital DNA With Offline Ambition Zoomlion (1157 HK/000157 CH) - Expect Accelerated Sales Growth in Nov Healthcare Global Enterprises Ltd - 5 Th December, 2025 Imdex (IMD): Reading the Strata 1. Halyk Bank — 7% NIM likely to be sustained into 2026 Halyk Bank reported a 13.8% y-o-y increase in net interest income in Q325 with a sustained high net interest margin (NIM) of 7.1% versus 7.3% in Q324 and robust loan book growth of 19.7% y-o-y (8.2% ytd). Combined with good cost discipline (the cost-to-income ratio (CIR) was 16.3% in Q325 vs 16.1% in Q324), this allowed the company to maintain an ROE above 30% (34.3% in Q325 on an annualised basis). Halyk preserved a strong capital base with a CET-1, Tier-1 and total capital ratio of 17.4% at end-September 2025 (with an indicative FY26e target of 17–19%) and local capital ratios of 18.3% versus the regulatory requirement for total capital (k2) of 12.0%.

Brief India: Wakefit Innovations IPO: Blending Digital DNA With Offline Ambition and more

In this briefing: Wakefit Innovations IPO: Blending Digital DNA With Offline Ambition Healthcare Global Enterprises Ltd - 5 Th December, 2025 Sedemac Mechatronics Ltd Pre-IPO Tearsheet Exencial Industry Tidings 05/12/2025 Milestone Gears Ltd Pre-IPO Tearsheet 1. Wakefit Innovations IPO: Blending Digital DNA With Offline Ambition Wakefit Innovations' INR 1,288.89 crore IPO signaling the pivot of India's largest D2C home brand toward institutional funding for accelerated omnichannel expansion . The fund utilization is heavily skewed towards offline growth and brand building, confirming a strategic shift from pure-play digital to a capital-intensive, integrated retail model. While the model mitigates supply chain risk through vertical integration , we must weigh the past profitability volatility and strategic roadmap for capturing India's rapidly formalizing home and furnishings sector . 2. Healthcare Global Enterprises Ltd - 5 Th December, 2025 HCG’s management hosted an investor and analyst interaction where the new CEO, Mr.

Brief India: Healthcare Global Enterprises Ltd - 5 Th December, 2025 and more

In this briefing: Healthcare Global Enterprises Ltd - 5 Th December, 2025 Sedemac Mechatronics Ltd Pre-IPO Tearsheet Exencial Industry Tidings 05/12/2025 Milestone Gears Ltd Pre-IPO Tearsheet Primer: Wakefit Innovations (1684049D IN) - Dec 2025 1. Healthcare Global Enterprises Ltd - 5 Th December, 2025 HCG’s management hosted an investor and analyst interaction where the new CEO, Mr. Manish Mattoo (a practicing anaesthesiologist and MBA in Finance), outlined a clear four-pillar strategy centered on clinical outcomes, profitable growth, capital efficiency, and patient experience. There will be a shift in the reporting framework from the “mature vs. new” category to regional clusters and oncology-appropriate KPIs such as ARPP and patient volumes. The medium-term aspiration is to grow ahead of the industry, improve EBITDA margins beyond the historical CAGR, and uplift company-level ROCE to 20% as more centres mature. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Healthcare Global Enterprises Q2 net dips 11 pc YoY

New Delhi, Cancer focused healthcare service provider Healthcare Global Enterprises has reported an … to Indian genetic diversity," HealthCare Global Enterprises (HCG) Founder and …

HealthCare Global Enterprises Ltd. engages in providing imaging and diagnostics services for cancer treatment. It focuses on maintenance of cancer treatment centers, imaging and diagnostics, and clinical trials and research services. It operates through the India and Outside India geographical segments. The company was founded on March 12, 1998 and is headquartered in Bangalore, India.

Current Price	588.70
Prev Close	643.00
Open	623.90
Dividend Yield	0.00%
50-Day Moving Average	694.90
Beta	0.08
Avg. Volume	143,705.38
PE Ratio	377.57

52-Week High	799.71
52-Week Low	513.30
Market Capitalization	95.37B
EPS (Annual)	0.9737
Price to Book	6.60
Revenue Per Employee	3.04M

Feed

News

Sentiment

Fundamentals

Info

HCG.NSE Fundamentals